Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. Its subsidiaries include SkinJect, Inc, and Medicus Pharma Inc. The Company’s wholly owned subsidiary, SkinJect, Inc (SkinJect), is focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumor cells. The Company’s wholly owned subsidiaries are focused on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. The Company investigates opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The Company is actively exploring expanding its drug development pipeline through qualified and accretive acquisitions and partnerships.
고수익 성장
회사의 순이익은 업계 선두를 달리고 있으며, 최근 연간 순이익은 미화 559.16에 달합니다.
공정한 가치
회사의 최신 PE은 -2.10로, 최근 3년 기준 중간 백분위 범위에 속합니다.
기관 매수
최신 기관 보유 주식 수는 10.21M주이며, 전 분기 대비 1.05% 증가했습니다.